XL Innovate acquires New Energy Risk

XL Group plc‘s venture capital fund XL Innovate has acquired New Energy Risk Inc. No financial terms were disclosed. New Energy Risk is a products provider for the cleantech sector. PRESS RELEASE DUBLIN, Ireland, Sept. 29, 2015 /PRNewswire/ — XL Group plc (“XL” or the “Company”) (NYSE: XL) announced today that XL Innovate, the venture capital initiative sponsored by the Company, has acquired all of the shares of New Energy Risk, Inc. Tom Hutton, Managing Partner of XL Innovate, said: “New Energy Risk has developed and delivered to the market unique performance warranty products which enable clean technology companies to obtain the project financing they need in order to grow. We look forward to the continued expansion of New Energy Risk under the leadership of CEO Tom Dickson who has a respected track record of leading companies that respond to market opportunities with creative solutions grounded in high quality analytics, underwriting and risk assessment. New Energy Risk is a great example of the kinds of businesses XL Innovate looks to grow. It develops and applies innovative insurance solutions based on engineering analytics, addressing new risks and underserved markets, and providing particularly high impact value for its clients.” Mr. Dickson has more than 25 years of experience in the insurance and reinsurance industry, including executive and underwriting leadership positions. He founded and ran Meetinghouse LLC, a private firm specializing in investment management for insurance, reinsurance and structured credit markets. Mr. Dickson previously served as CEO and Chief Underwriting Officer of the Centre Group, an innovative international insurance and reinsurance group. Commenting on his new role, Mr. Dickson said: “I’m excited to be back in an underwriting role, and particularly excited by the opportunity to address such high value client relationships throughout the world. At New Energy Risk, we collaborate closely with customers, brokers, financiers and other intermediaries in developing customized policies to encourage customer acceptance and support financing of renewable and clean energy technologies.” In 2013, New Energy Risk launched an innovative technology performance insurance product for the cleantech industry, which has been used by companies like Bloom Energy, a Silicon Valley based fuel cell company. Over the past three years, New Energy Risk has worked with XL and Munich Re to insure the performance of Bloom Energy’s technology, improving the financing in support of the installation of nearly 65 megawatts of clean, reliable electricity. About XL Innovate XL Innovate is an XL sponsored venture capital initiative focused on making investments in companies with businesses that address the world’s most complex risk and ensuring the relevancy of the insurance industry today and into the future. XL Innovate will seek to invest in companies that strive to create opportunities outside of the traditional underwriting space by finding ways to underwrite currently uninsured risks. To learn more, visit www.xlinnovate.com About New Energy Risk New Energy Risk is a provider of innovative data analytics, strategic consulting and financial risk transfer solutions to the renewable energy industry worldwide. It was founded by Tom Hutton in 2011 to serve as a risk assessor and intermediary between clean-energy innovators and insurers. For more information, visit www.newenergyrisk.com. About Bloom Energy Bloom Energy is a provider of breakthrough solid oxide fuel cell technology generating clean, highly-efficient on-site power from multiple fuel sources. The company was founded in 2001 with a mission to make clean, reliable energy affordable for everyone in the world. Bloom Energy Servers are currently producing power for several Fortune 500 companies including Google, Walmart, AT&T, eBay, Staples, The Coca-Cola Company, as well as notable non-profit organizations such as Caltech and Kaiser Permanente. For more information, visit www.bloomenergy.com. About XL Group plc XL Group plc (NYSE: XL), through its subsidiaries and under the XL Catlin brand, is a global insurance and reinsurance company providing property, casualty and specialty products to industrial, commercial and professional firms, insurance companies and other enterprises throughout the world. Clients look to XL Catlin for answers to their most complex risks and to help move their world forward. To learn more, visit www.xlcatlin.com.

Here is the original post:
XL Innovate acquires New Energy Risk

PE-backed BioClinica buys Synowledge

BioClinica, which is backed by Water Street Healthcare Partners and JLL Partners, has acquired Synowledge. No financial terms were disclosed, Based in Miami, Florida, Synowledge is a pharmaceutical and biotech company. PRESS RELEASE NEWTOWN, Pa., Sept. 21, 2015 /PRNewswire/ — BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that it has acquired Synowledge to expand its offering into the growing drug safety and regulatory business process outsourcing market. Headquartered in Miami, Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analyzing and reporting adverse drug events. “This acquisition extends BioClinica’s solutions into an important new area for our customers,” said BioClinica President and Chief Executive Officer John Hubbard. “Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events. Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.” Since its founding in 2006, Synowledge has grown rapidly to serve many of the world’s leading pharmaceutical and biotechnology organizations. The company offers pharmacovigilance services across all therapeutic areas and stages of drug development, including case processing, aggregate reporting, medical literature review, call center support and signal detection. Synowledge employs a highly skilled global workforce of more than 500 people who provide customers with around-the-clock expertise and support remotely or onsite. The company also offers information technology services for drug safety applications. Sankesh Abbhi, who founded Synowledge, said, “We are very pleased to become part of BioClinica. Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.” Effective immediately, Mr. Abbhi will serve as senior vice president and head of global safety and regulatory solutions. He will report to Mukhtar Ahmed, president of BioClinica’s eClinical Solutions Division. “Synowledge is a proven industry leader in the adoption of pharmacovigilance and regulatory technologies,” said Mr. Ahmed. “With its depth of expertise in business process execution, data analysis and application-managed services, we will further extend our eClinical product and services portfolio so that we can provide our customers with a comprehensive offering that spans across the life sciences landscape.” About BioClinica, Inc. BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica’s experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com. About Synowledge Synowledge is a specialized Pharmacovigilance, Regulatory Affairs and IT services provider that assists and enables small, medium and large life sciences organizations to satisfy their global regulatory requirements. The Synowledge team consists of highly qualified and skilled experts who are committed to helping companies meet and exceed the challenging demands of the R&D lifecycle. Our comprehensive outsourcing solutions cover all therapeutic areas and combine the unique strengths and knowledge of industry leading experts. Our commitment to quality allows us to deliver accurate, consistent, and robust solutions to the life sciences industry. Synowledge was founded in 2006 and is headquartered in Miami, Florida. Synowledge has global offices in North America, Europe, India, and Japan. For more information, please visit http://www.synowledge.com

Read more from the original source:
PE-backed BioClinica buys Synowledge